Imagine this scenario: A new investigational drug for the treatment of pancreatic cancer is in early phase III clinical trials. Phase II data published show a reasonable safety profile and early indication of effectiveness. There is a buzz in the clinical community, members of patient advocacy groups and a growing number pancreatic cancer blogs buzz with activity. Read this Whitepaper to find out more!
Home » Access Portal Assets » Expanded Access Programs: Navigating the When, Who and How to Deliver a Successful Program
Thank you for registering!
Error - something went wrong!
Innovation In Real-World Research: Driving Value Through Leading-Edge Technology, Process and Insight
Read this paper about what the next five years will hold for the industry!
Most Recent Flipbooks
PAN EUROPEAN HTA - Where have we been, where are we going?
Integrating Expertise For Product Success
Creating aligned and integrated physician and payer-focused value propositions
What Makes a Good Evidence Generation Plan?
This article will introduce some of the key factors and considerations for a successful evidence generation plan with further articles presenting additional details on specific components of the EGP.
Early Economic Modelling To Inform Decision Making
Innovative trial design Health Economics Webinar PPT
Closing the minority gap maximizing ethnic diversity in clinical trials article
This topical article examines the role of the CRO in using culturally specific strategies to engage under-represented patient populations, in order to boost trial recruitment.
HTAi Poster_The Furture Model of Oncology Reimbursement
HTAi Poster_Future Trends for Managed Access in UK
The Resurrection of the Cost-Minimization Approach in England
Would a HST Be Approved in England Under the New Nice Guidance?
Your Money or Your Life? Are Price Negotiations HTA Best Practice?
The Impact of pCODR Coming Under the Remit of CADTH - 3 Year Update
Orphan Diseases Translating Expedited Regulatory approval into Reimbursement success article
Innovative Clinical Trial Designs — Welcomed By Regulators But What About The Payers?
Presentation Slides: Early Engagement Strategies Webinar
Promoting the patient voice in evidence generation and global market-access planning
Presentation from the Medical Affairs Leaders Forum, London. February 27 - March 01, 2018
Safety Services: A tailored solution to support the needs of large companies
What to look for in a partner to support biosimilar initiatives
This article looks at some of the trends in biosimilars, including three key errors you need to avoid. Particularly, as it pertains to underestimating your risk management plan.
The Importance of QPPVs in Pharmacovigilance